Akebia Therapeutics
(AKBA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 56,953 | 90,466 | 144,761 | 143,893 | 174,562 |
| Receivables | 17,781 | 40,284 | 23,094 | 81,869 | 64,582 |
| Inventories | 20,604 | 21,568 | 40,039 | 36,272 | 39,422 |
| TOTAL | $120,719 | $185,182 | $237,512 | $304,163 | $302,687 |
| Non-Current Assets | |||||
| PPE Net | 4,816 | 5,214 | 5,622 | 6,035 | 6,451 |
| Intangibles | 118,127 | 131,128 | 136,148 | 145,159 | 154,169 |
| Other Non-Current Assets | 33,196 | 34,530 | 56,612 | 66,447 | 72,049 |
| TOTAL | $156,139 | $170,872 | $198,382 | $217,641 | $232,669 |
| Total Assets | $276,858 | $356,054 | $435,894 | $521,804 | $535,356 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 24,000 | 32,000 | 65,947 | 98,158 | 97,848 |
| Accounts payable and accrued liabilities | 12,577 | 18,021 | 19,708 | 24,944 | 19,466 |
| Accrued Expenses | 46,367 | 75,777 | 87,364 | 91,284 | 109,660 |
| Other current liabilities | N/A | N/A | 13,681 | 14,247 | 16,500 |
| TOTAL | $82,944 | $129,536 | $187,965 | $233,680 | $253,914 |
| Non-Current Liabilities | |||||
| Long Term Debt | 26,296 | 34,078 | N/A | N/A | N/A |
| Deferred Revenues | 0 | 3,738 | 1,265 | 5,047 | 10,440 |
| Other Non-Current Liabilities | 138,674 | 143,914 | 190,780 | 150,795 | 189,970 |
| TOTAL | $208,266 | $221,288 | $234,076 | $225,824 | $255,326 |
| Total Liabilities | $291,210 | $350,824 | $422,041 | $459,504 | $509,240 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 185,928 | 184,248 | 183,962 | 183,849 | 183,533 |
| Common Shares | 2 | 2 | 2 | 2 | 2 |
| Retained earnings | -1,579,130 | -1,557,025 | -1,545,361 | -1,493,496 | -1,522,772 |
| Other shareholders' equity | 6 | 6 | 6 | 6 | 6 |
| TOTAL | $-14,352 | $5,230 | $13,853 | $62,300 | $26,116 |
| Total Liabilities And Equity | $276,858 | $356,054 | $435,894 | $521,804 | $535,356 |